Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor

Detalhes bibliográficos
Autor(a) principal: Persson, Emma
Data de Publicação: 2019
Outros Autores: Souza, Pedro P.C. [UNESP], Floriano-Marcelino, Thais [UNESP], Conaway, Howard Herschel, Henning, Petra, Lerner, Ulf H.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3389/fimmu.2019.01164
http://hdl.handle.net/11449/187826
Resumo: Background and Purpose: The gp130 family of cytokines signals through receptors dimerizing with the gp130 subunit. Downstream signaling typically activates STAT3 but also SHP2/Ras/MAPK pathways. Oncostatin M (OSM) is a unique cytokine in this family since the receptor (OSMR) activates a non-redundant signaling pathway by recruitment of the adapter Shc1. We have studied the functional relevance of Shc1 for OSM-induced bone resorption. Experimental Approach: Osteoblasts were stimulated with OSM and STAT3 and Shc1 activations were studied using real-time PCR and Western blots. The role of STAT3 and Shc1 for OSM-induced RANKL expression and osteoclast formation was studied by silencing their mRNA expressions. Effects of OSM were compared to those of the closely related cytokine leukemia inhibitory factor (LIF). Key Results: OSM, but not LIF, induced the mRNA and protein expression of Shc1 and activated phosphorylation of Shc1 in the osteoblasts. Silencing of Shc1 decreased OSM-induced activation of STAT3 and RANKL expression. Silencing of STAT3 had no effect on activation of Shc1, but prevented the OSM-mediated increase of RANKL expression. Silencing of either Shc1 or STAT3 in osteoblasts decreased formation of osteoclasts in OSM-stimulated co-cultures of osteoblasts and macrophages. In agreement with these observations, OSM was a more potent and robust stimulator than LIF of RANKL formation and bone resorption in mouse calvariae and osteoclast formation in bone marrow cultures. Conclusions and Implications: Activation of the Shc1-dependent STAT3 signaling is crucial for OSM-induced osteoclast formation. Inhibition of Shc1 is a potential mechanism to specifically inhibit OSM-induced bone resorption.
id UNSP_90485663e5be77272190c6b5ba2c4f1b
oai_identifier_str oai:repositorio.unesp.br:11449/187826
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factorBone resorptionLIFOSMOsteoclastRANKLShc1Background and Purpose: The gp130 family of cytokines signals through receptors dimerizing with the gp130 subunit. Downstream signaling typically activates STAT3 but also SHP2/Ras/MAPK pathways. Oncostatin M (OSM) is a unique cytokine in this family since the receptor (OSMR) activates a non-redundant signaling pathway by recruitment of the adapter Shc1. We have studied the functional relevance of Shc1 for OSM-induced bone resorption. Experimental Approach: Osteoblasts were stimulated with OSM and STAT3 and Shc1 activations were studied using real-time PCR and Western blots. The role of STAT3 and Shc1 for OSM-induced RANKL expression and osteoclast formation was studied by silencing their mRNA expressions. Effects of OSM were compared to those of the closely related cytokine leukemia inhibitory factor (LIF). Key Results: OSM, but not LIF, induced the mRNA and protein expression of Shc1 and activated phosphorylation of Shc1 in the osteoblasts. Silencing of Shc1 decreased OSM-induced activation of STAT3 and RANKL expression. Silencing of STAT3 had no effect on activation of Shc1, but prevented the OSM-mediated increase of RANKL expression. Silencing of either Shc1 or STAT3 in osteoblasts decreased formation of osteoclasts in OSM-stimulated co-cultures of osteoblasts and macrophages. In agreement with these observations, OSM was a more potent and robust stimulator than LIF of RANKL formation and bone resorption in mouse calvariae and osteoclast formation in bone marrow cultures. Conclusions and Implications: Activation of the Shc1-dependent STAT3 signaling is crucial for OSM-induced osteoclast formation. Inhibition of Shc1 is a potential mechanism to specifically inhibit OSM-induced bone resorption.Department of Molecular Periodontology Umeå UniversityBone Biology Research Group Department of Physiology and Pathology School of Dentistry São Paulo State University (UNESP)School of Dentistry Federal University of GoiásDepartment of Physiology and Biophysics University of Arkansas for Medical SciencesDepartment of Internal Medicine and Clinical Nutrition Centre for Bone and Arthritis Research Institute for Medicine Sahlgrenska Academy University of GothenburgDepartment of Radiation Sciences Umeå UniversityBone Biology Research Group Department of Physiology and Pathology School of Dentistry São Paulo State University (UNESP)Umeå UniversityUniversidade Estadual Paulista (Unesp)Universidade Federal de Goiás (UFG)University of Arkansas for Medical SciencesUniversity of GothenburgPersson, EmmaSouza, Pedro P.C. [UNESP]Floriano-Marcelino, Thais [UNESP]Conaway, Howard HerschelHenning, PetraLerner, Ulf H.2019-10-06T15:48:27Z2019-10-06T15:48:27Z2019-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3389/fimmu.2019.01164Frontiers in Immunology, v. 10, n. MAY, 2019.1664-3224http://hdl.handle.net/11449/18782610.3389/fimmu.2019.011642-s2.0-85068238235Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengFrontiers in Immunologyinfo:eu-repo/semantics/openAccess2021-10-23T19:49:53Zoai:repositorio.unesp.br:11449/187826Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462021-10-23T19:49:53Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
title Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
spellingShingle Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
Persson, Emma
Bone resorption
LIF
OSM
Osteoclast
RANKL
Shc1
title_short Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
title_full Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
title_fullStr Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
title_full_unstemmed Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
title_sort Activation of Shc1 allows oncostatin M to induce RANKL and osteoclast formation more effectively than leukemia inhibitory factor
author Persson, Emma
author_facet Persson, Emma
Souza, Pedro P.C. [UNESP]
Floriano-Marcelino, Thais [UNESP]
Conaway, Howard Herschel
Henning, Petra
Lerner, Ulf H.
author_role author
author2 Souza, Pedro P.C. [UNESP]
Floriano-Marcelino, Thais [UNESP]
Conaway, Howard Herschel
Henning, Petra
Lerner, Ulf H.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Umeå University
Universidade Estadual Paulista (Unesp)
Universidade Federal de Goiás (UFG)
University of Arkansas for Medical Sciences
University of Gothenburg
dc.contributor.author.fl_str_mv Persson, Emma
Souza, Pedro P.C. [UNESP]
Floriano-Marcelino, Thais [UNESP]
Conaway, Howard Herschel
Henning, Petra
Lerner, Ulf H.
dc.subject.por.fl_str_mv Bone resorption
LIF
OSM
Osteoclast
RANKL
Shc1
topic Bone resorption
LIF
OSM
Osteoclast
RANKL
Shc1
description Background and Purpose: The gp130 family of cytokines signals through receptors dimerizing with the gp130 subunit. Downstream signaling typically activates STAT3 but also SHP2/Ras/MAPK pathways. Oncostatin M (OSM) is a unique cytokine in this family since the receptor (OSMR) activates a non-redundant signaling pathway by recruitment of the adapter Shc1. We have studied the functional relevance of Shc1 for OSM-induced bone resorption. Experimental Approach: Osteoblasts were stimulated with OSM and STAT3 and Shc1 activations were studied using real-time PCR and Western blots. The role of STAT3 and Shc1 for OSM-induced RANKL expression and osteoclast formation was studied by silencing their mRNA expressions. Effects of OSM were compared to those of the closely related cytokine leukemia inhibitory factor (LIF). Key Results: OSM, but not LIF, induced the mRNA and protein expression of Shc1 and activated phosphorylation of Shc1 in the osteoblasts. Silencing of Shc1 decreased OSM-induced activation of STAT3 and RANKL expression. Silencing of STAT3 had no effect on activation of Shc1, but prevented the OSM-mediated increase of RANKL expression. Silencing of either Shc1 or STAT3 in osteoblasts decreased formation of osteoclasts in OSM-stimulated co-cultures of osteoblasts and macrophages. In agreement with these observations, OSM was a more potent and robust stimulator than LIF of RANKL formation and bone resorption in mouse calvariae and osteoclast formation in bone marrow cultures. Conclusions and Implications: Activation of the Shc1-dependent STAT3 signaling is crucial for OSM-induced osteoclast formation. Inhibition of Shc1 is a potential mechanism to specifically inhibit OSM-induced bone resorption.
publishDate 2019
dc.date.none.fl_str_mv 2019-10-06T15:48:27Z
2019-10-06T15:48:27Z
2019-01-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3389/fimmu.2019.01164
Frontiers in Immunology, v. 10, n. MAY, 2019.
1664-3224
http://hdl.handle.net/11449/187826
10.3389/fimmu.2019.01164
2-s2.0-85068238235
url http://dx.doi.org/10.3389/fimmu.2019.01164
http://hdl.handle.net/11449/187826
identifier_str_mv Frontiers in Immunology, v. 10, n. MAY, 2019.
1664-3224
10.3389/fimmu.2019.01164
2-s2.0-85068238235
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Frontiers in Immunology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799964648826470400